Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN954298 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Protein Kinase, AMP-Activated, alpha 2 Catalytic Subunit (PRKAA2) (AA 148-177), (Middle Region), (Thr172) antibody
- Antibody type
- Polyclonal
- Description
- Affinity chromatography on Protein A
- Reactivity
- Human
- Host
- Rabbit
- Epitope
- AA 148-177, Middle Region, Thr172
- Vial size
- 0.4 mL
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
- Handling
- Avoid repeated freezing and thawing.
Submitted references Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation.
Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B, Carling D, Thompson CB, Jones RG, Berger SL
Science (New York, N.Y.) 2010 Sep 3;329(5996):1201-5
Science (New York, N.Y.) 2010 Sep 3;329(5996):1201-5
Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.
Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D, Florez JC, Diabetes Prevention Program Research Group.
Diabetes 2010 Oct;59(10):2672-81
Diabetes 2010 Oct;59(10):2672-81
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators.
Diabetes care 2010 Oct;33(10):2250-3
Diabetes care 2010 Oct;33(10):2250-3
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Ruaño G, Thompson PD, Kane JP, Pullinger CR, Windemuth A, Seip RL, Kocherla M, Holford TR, Wu AH
Pharmacogenomics 2010 Jul;11(7):959-71
Pharmacogenomics 2010 Jul;11(7):959-71
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- FACS
